|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date01 Jan 1985 |
|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
美洛昔康纳米晶注射液用于成人腹腔镜术后镇痛的多中心、随机、双盲、安慰剂平行对照的III期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of meloxicam nanocrystal injection for postoperative analgesia in adults with laparoscopic surgery
评价美洛昔康纳米晶注射液用于成人腹腔镜术后镇痛的有效性与安全性
[Translation] To evaluate the efficacy and safety of meloxicam nanocrystal injection for postoperative analgesia in adults with laparoscopic surgery
一项评价雾化吸入XYP-001在健康成年人及特发性肺纤维化患者人群中安全性、耐受性以及药代动力学特征的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of nebulized XYP-001 in healthy adults and patients with idiopathic pulmonary fibrosis
主要研究目的(SAD):评价单次雾化吸入XYP-001后受试者的安全性和耐受性。
次要研究目的(SAD):评价单次雾化吸入XYP-001后受试者的XYP-001及其代谢产物的药代动力学特征。
主要研究目的(MAD):评价多次雾化吸入XYP-001后受试者的安全性和耐受性。
次要研究目的(MAD):评价多次雾化吸入XYP-001后受试者的XYP-001及其代谢产物的药代动力学特征及稳态情况; 评价雾化吸入XYP-001后IPF受试者的XYP-001及其代谢产物的痰液药物峰浓度和谷浓度。
[Translation] Primary study objective (SAD): To evaluate the safety and tolerability of subjects after a single nebulized inhalation of XYP-001.
Secondary study objective (SAD): To evaluate the pharmacokinetic characteristics of XYP-001 and its metabolites in subjects after a single nebulized inhalation of XYP-001.
Primary study objective (MAD): To evaluate the safety and tolerability of subjects after multiple nebulized inhalations of XYP-001.
Secondary study objective (MAD): To evaluate the pharmacokinetic characteristics and steady-state of XYP-001 and its metabolites in subjects after multiple nebulized inhalations of XYP-001; To evaluate the sputum peak and trough drug concentrations of XYP-001 and its metabolites in IPF subjects after nebulized inhalation of XYP-001.
沙美特罗替卡松吸入粉雾剂治疗成人哮喘有效性和安全性的多中心、随机、盲法、阳性平行对照临床研究
[Translation] A multicenter, randomized, blinded, positive parallel controlled clinical study on the efficacy and safety of salmeterol-fluticasone inhalation powder in the treatment of adult asthma
评价沙美特罗替卡松吸入粉雾剂治疗成人哮喘的有效性和安全性
[Translation] To evaluate the efficacy and safety of salmeterol/fluticasone inhalation powder in the treatment of asthma in adults
100 Clinical Results associated with Shenzhen Haibin Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shenzhen Haibin Pharmaceutical Co., Ltd.
100 Deals associated with Shenzhen Haibin Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shenzhen Haibin Pharmaceutical Co., Ltd.